Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HIF1A | Q16665 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 3/20 | 0.46 |
| ▸ | NT5E | P21589 | 1/20 | 0.46 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | GDA | Q9Y2T3 | 1/20 | 0.43 |
| ▸ | HSPA5 | P11021 | 1/20 | 0.36 |
| ▸ | HSPA8 | P11142 | 1/20 | 0.36 |
| ▸ | GMNN | O75496 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
| ▸ | DNMT1 | P26358 | 1/20 | 0.35 |
| ▸ | THPO | P40225 | 1/20 | 0.35 |
| ▸ | MTOR | P42345 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | RAB9A | P51151 | 1/20 | 0.35 |
| ▸ | BLM | P54132 | 1/20 | 0.35 |
| ▸ | HBB | P68871 | 1/20 | 0.35 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.35 |
| ▸ | PNP | P00491 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| 2,6-Diaminopurine SCHEMBL10774603 | 0.89 | PDPK1 (0.59) | LMNAPDPK1GDAGMNNALDH1A1 | |
| 2,6-Diaminopurine SCHEMBL6241914 | 0.89 | PDPK1 (0.59) | LMNAPDPK1GDAGMNNALDH1A1 | |
| 2,6-Diaminopurine SCHEMBL2934952 | 0.89 | PDPK1 (0.59) | LMNAPDPK1GDAGMNNALDH1A1 | |
| Ribose (Furanose) SCHEMBL2935366 | 0.86 | PDPK1 (0.42) | HIF1ALMNANT5EPDPK1GDA | |
| SCHEMBL4291802 | 0.84 | CA5A (0.52) | NT5EADORA1SMN1; SMN2 | |
| Adenine SCHEMBL7746165 | 0.82 | PI4KA (0.58) | HIF1ALMNAHSPA5HSPA8ALDH1A1 | |
| Adenine SCHEMBL580228 | 0.82 | PI4KA (0.58) | HIF1ALMNAHSPA5HSPA8ALDH1A1 | |
| Adenine SCHEMBL38386 | 0.82 | PI4KA (0.58) | HIF1ALMNAHSPA5HSPA8ALDH1A1 | |
| Adenine SCHEMBL7624128 | 0.82 | PI4KA (0.58) | HIF1ALMNAHSPA5HSPA8ALDH1A1 | |
| Dextrose SCHEMBL7886725 | 0.81 | PI4KA (0.56) | HIF1ALMNAHSPA5HSPA8ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240261333-A1 | NOVEL TARGETS FOR ENHANCING ANTI-TUMOR IMMUNITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-08 | — | — | US | claimed |
| WO-2022256620-A1 | NOVEL TARGETS FOR ENHANCING ANTI-TUMOR IMMUNITY | THE BROAD INSTITUTE, INC. (US) | 2022-12-08 | — | — | WO | claimed |
| US-20240376143-A1 | SELECTION INHIBITION OF DNA POLYMERASE BETA BY A COVALENT INHIBITOR | THE JOHNS HOPKINS UNIVERSITY | 2024-11-14 | — | — | US | disclosed |
| US-20240261333-A1 | NOVEL TARGETS FOR ENHANCING ANTI-TUMOR IMMUNITY | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-08 | — | — | US | disclosed |
| WO-2022256620-A1 | NOVEL TARGETS FOR ENHANCING ANTI-TUMOR IMMUNITY | THE BROAD INSTITUTE, INC. (US) | 2022-12-08 | — | — | WO | disclosed |
| WO-2022245782-A1 | SELECTIVE INHIBITION OF DNA POLYMERASE BETA BY A COVALENT INHIBITOR | THE JOHNS HOPKINS UNIVERSITY (US) | 2022-11-24 | — | — | WO | disclosed |
| EP-3456718-B1 | ISATIN-DERIVED COMPOUNDS, USE OF THE COMPOUNDS FOR THE TREATMENT OF AIDS AND HBV INFECTIONS | FUNDACAO OSWALDO CRUZ (BR) | 2021-02-17 | — | — | EP | disclosed |
| US-20170292946-A1 | METHODS FOR DIAGNOSIS, PROGNOSIS AND METHODS OF TREATMENT | NODALITY, INC. | 2017-10-12 | — | — | US | disclosed |
| EP-1646363-B1 | INTRAVAGINAL DRUG DELIVERY DEVICES | WARNER CHILCOTT IRELAND LTD (IE) | 2013-10-16 | — | — | EP | disclosed |
| US-20090258843-A1 | Compositions Containing Antiviral Compounds and Methods of Using the Same | MALLINCKRODT INC. (US) | 2009-10-15 | — | — | US | disclosed |
| US-20070142317-A1 | Topical composition for treatment of skin disorders | QLT USA, INC. (US) | 2007-06-21 | — | — | US | disclosed |
| US-5430045-A | Administering an L-2-oxothiazolidine-4-carboxylate to patient receiving AZT | FREE RADICAL SCIENCES, INC. (US) | 1995-07-04 | — | — | US | disclosed |
| EP-0647444-A1 | L-2-oxothiazolidine-4-carboxylate and other stimulators of intracellular glutathione synthesis for reducing or preventing bone marrow hypoplasia | Transcend Therapeutics, Inc. (US) | 1995-04-12 | — | — | EP | disclosed |
| EP-0624368-A2 | Use of a composition for stimulating the synthesis of glutathione in the manufacture of a medicament for the treatment of acquired immune deficiency syndrome | Transcend Therapeutics, Inc. (US) | 1994-11-17 | — | — | EP | disclosed |
| EP-0572110-A2 | Method of reducing or preventing toxicity associated with antiretroviral therapy by stimulation of the intracellular gluthatione level | Transcend Therapeutics, Inc. (US) | 1993-12-01 | — | — | EP | disclosed |
| US-5145840-A | Treatment of virac and bacterial infections; aids | BURROUGHS WELLCOME CO. (US) | 1992-09-08 | — | — | US | disclosed |
| EP-0460045-A1 | NUCLEOSIDE ANALOGUES | UNIVERSITY COLLEGE LONDON (GB) | 1991-12-11 | — | — | EP | disclosed |
| EP-0445201-A1 | NUCLEOSIDE ANALOGUES | MEDICAL RESEARCH COUNCIL (GB) | 1991-09-11 | — | — | EP | disclosed |
| WO-1990010012-A1 | NUCLEOSIDE ANALOGUES | UNIVERSITY COLLEGE LONDON (GB) | 1990-09-07 | — | — | WO | disclosed |
| WO-1990005736-A2 | NUCLEOSIDE ANALOGUES | MEDICAL RESEARCH COUNCIL (GB) | 1990-05-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142317-A1 | Topical composition for treatment of skin disorders | CDA, ADA, DCTD | HIF1A 2768/4885LMNA 3214/4885NT5E 37/4885 |
| US-20240376143-A1 | SELECTION INHIBITION OF DNA POLYMERASE BETA BY A COVALENT INHIBITOR | POLB, POLA1, POLH | HIF1A 3503/4885LMNA 2535/4885NT5E 3490/4885 |
| US-20090258843-A1 | Compositions Containing Antiviral Compounds and Methods of Using the Same | EIF2AK2, MAVS, IRF3 | HIF1A 1962/4885LMNA 3366/4885NT5E 2725/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.